Evidence map›Paper›PMID 40894903›Full record

ArticleiScience2025

DNA-encoded library screening uncovers potent DNMT2 inhibitors targeting a cryptic allosteric binding site.

Ariane F Frey, Merlin Schwan, Annabelle C Weldert, Valerie Kadenbach, Jürgen Kopp, Zarina Nidoieva, Robert A Zimmermann, Lukas Gleue, Collin Zimmer, Marko Jörg and 4 more

Abstract read
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ariane F FreyInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Merlin SchwanHeidelberg University Biochemistry Center (BZH), 69120 Heidelberg, Germany.
Annabelle C WeldertInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Valerie KadenbachInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Jürgen KoppHeidelberg University Biochemistry Center (BZH), 69120 Heidelberg, Germany.
Zarina NidoievaInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Robert A ZimmermannInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Lukas GleueInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Collin ZimmerInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Marko JörgInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Kristina FriedlandInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Mark HelmInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.
Irmgard SinningHeidelberg University Biochemistry Center (BZH), 69120 Heidelberg, Germany.
Fabian BarthelsInstitute of Pharmaceutical and Biomedical Sciences (IPBS), 55128 Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNMT2 (TRDMT1) is a human RNA methyltransferase implicated in various disease processes. However, small-molecule targeting of DNMT2 remains challenging due to poor selectivity and low cellular availability of known

Indexed as

BiochemistryMolecular StructureProperties of biomoleculesStructural biology

Identifiers

PMID40894903
PMCPMC12396291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.